ERBB2 juxtamembrane domain (trastuzumab binding site) gene mutation is a rare event in invasive breast cancers overexpressing the ERBB2 gene

Modern Pathology

Volumn 24, Issue 8, 2011, Pages 1055-1059

  Khoury, Thaer ^a   Mojica, Wilfrido ^b   Hicks, David ^c   Starostik, Petr ^a   Ademuyiwa, Foluso ^a   Janarthanan, Bagirathan ^d   Cheney, Richard T ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b Department of Pathology   (United States)

^c ROCHESTER GENERAL HOSPITAL   (United States)

^d FLORIDA HOSPITAL   (United States)

Author keywords

breast cancer; ERBB2; gene mutation; trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BINDING SITE; BREAST CANCER; EXON; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; GENE SEQUENCE; HUMAN; JUXTAMEMBRANE DOMAIN; LASER CAPTURE MICRODISSECTION; MAJOR CLINICAL STUDY; MEDICAL HISTORY; MISSENSE MUTATION; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DOMAIN; TUMOR CELL;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BINDING SITES; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LASERS; MICRODISSECTION; MIDDLE AGED; MUTATION, MISSENSE; NEOPLASM INVASIVENESS; RECEPTOR, ERBB-2;

EID: 79961020935     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2011.64     Document Type: Article

References (29)

1. Yaziji H, Goldstein LC, Barry TS, et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 2004;291:1972-1977. (Pubitemid 38544278)
2. Owens MA, Horten BC, Da Silva MM. ERBB2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 2004;5:63-69. (Pubitemid 38821193)
3. Olayioye MA, Neve RM, Lane HA, et al. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000;19:3159-3167. (Pubitemid 30428195)
4. Harvey JM, Clark GM, Osborne CK. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for prediction response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-1481. (Pubitemid 29220854)
5. Cobleigh MA, Vogel CL, Tripathy D. Multinational study of the efficacy and safety of humanized anti-ERBB2 monoclonal antibody in women who have ERBB2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-2648. (Pubitemid 29415219)
6. Hancock MC, Langton BC, Chan T. A monoclonal antibody against the C-erb-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res 1991;51:4575-4580.
7. Stancovski I, Hurwitz E, Leitner O. Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth. Proc Natl Acad Sci USA 1991;88:8691-8695. (Pubitemid 21915423)
8. Pegram MD, Konecny GE, O'Callaghan C, et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004;96:739-749. (Pubitemid 38771819)
9. Nahta R, Esteva FJ. Herceptin. Mechanisms of action and resistance. Cancer Lett 2006;232:123-138.
10. Normanno N, Maiello MR, De Luca A. Epidermal growth factor receptortyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action? J Cell Physiol 2003;194:13-19. (Pubitemid 35424223)
11. Cho HS, Mason KR, Amyar KX, et al. Structure of the extracellular region of ERBB2 alone and in complex with the Herceptin. Nature 2003;421:756-760.
12. Cooley S, Burns LJ, Repka T, et al. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and ERBB2/neu. Exp Hematol 1999;27:1533-1541. (Pubitemid 29458428)
13. Sliwokowski MX, Lofgren JA, Lewis GD. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 1999;26:60-70. (Pubitemid 29411434)
14. Baselga J, Albanell J. Mechanism of action of anti-ERBB2 monoclonal antibodies. Ann Oncol 2001;12:35-41.
15. Moniaux N, Andrianifahanana M, Brand RE, et al. Multiple roles of mucins in pancreatic cancer, a lethal and challenging malignancy. Br J Cancer 2004;91: 1633-1638. (Pubitemid 39546133)
16. Carraway KL, Perez A, Idris N, et al. Muc4/sialomucin complex in the mammary gland and breast cancer. J Mammary Gland Biol Neoplasia 2001;6:323-337.
17. Nahta R, Takahashi T, Ueno NT, et al. P27Kip1 downregulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res 2004;64:3981-3986. (Pubitemid 38697313)
18. Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004;6:117-127. (Pubitemid 39485684)
19. Lu CH, Wyszomierski SL, Tseng LM, et al. Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res 2007;13:5883-3888.
20. Nahta R, Yuan LXH, Zhang B, et al. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 2005;65:11118-11128. (Pubitemid 41713383)
21. Chung Y-L, Sheu M-L, Yang S-C, et al. Resistance to tamoxifen-induced apoptosis is associated with direct interaction between ERBB2/neu and cell membrane estrogen receptor in breast cancer. Int J Cancer 2002;97:306-312. (Pubitemid 34049020)
22. du Manoir JM, Francia G, Man S, et al. Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts. Clin Cancer Res 2006;12:904-916. (Pubitemid 43259873)
23. Khoury T, Kanehira K, Wang D, et al. Breast carcinoma with amplified ERBB2: a gene expression signature specific for trastuzumab resistance and poor prognosis. Mod Pathol 2010;23:1364-1378.
24. Stephens P, Hunter C, Bignell G, et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 2004;30:525-526.
25. Lee JW, Soung YH, Seo SH, et al. Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. Clin Cancer Res 2006;12:57-61. (Pubitemid 43166176)
26. Zito CI, Riches D, Kolmakova J, et al. Direct resequencing of the complete ERBB2 coding sequence reveals an absence of activating mutations in ERBB2 amplified breast cancer. Genes Chromosomes Cancer 2008;47: 633-638. (Pubitemid 351748349)
27. Gori S, Ludovini V, Colozza M, et al. ERBB2, EGFR, PIK3CA mutations in ERBB2+ metastatic breast cancer (MBC) patients (pts) treated with trastuzumab (T): incidence and correlation with response. Clin Oncol 2008;26(suppl): Abstract 1031.
28. Khoury T, Mojica W, Hicks DG, et al. Trastuzumab binding site mutations in ERBB2 positive invasive breast cancer: a potential predictor of less aggressive disease and trastuzumab resistance. Breast Cancer Res Treat 2006;100(Suppl 1):S31 (Abstract 308).
29. Staaf J, Ringnér M, Vallon-Christersson J, et al. Identification of subtypes in human epidermal growth factor receptor 2-positive breast cancer reveals a gene signature prognostic of outcome. J Clin Oncol 2010;10: 1813-1820.